The sensitivity to PIM inhibitor AZD1208 varied among AML cell lines: MOLM-16 was extremely responsive to AZD1208, requiring the lowest concentration to induce cell growth inhibition and cell death, followed by OCI-AML3, MV4;11, and MOLM-13, which required progressively higher doses. Here, RUNX2 is linked to acute myeloid leukemia.